Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16749440 | 0.83 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL17924657 | 0.83 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL16749351 | 0.83 | NR1H2 (0.38) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL30693992 | 0.81 | ALDH1A1 (0.34) | CHRM2CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL23104345 | 0.81 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HSD17B10SMN1; SMN2 | |
| SCHEMBL30694037 | 0.79 | POLB (0.38) | POLBL3MBTL1 | |
| SCHEMBL17294892 | 0.78 | RORC (0.40) | MEN1KMT2AKDM1ATSHR | |
| SCHEMBL903377 | 0.78 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL16584652 | 0.78 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL16584653 | 0.78 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522593-B2 | Azacycloalkyl carbonyl cyclic amine compound | ALIVEXIS, INC. (JP) | 2026-01-13 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | ALIVEXIS, INC. (JP) | 2025-05-22 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4538264-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | Alivexis, Inc. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119317620-A | Azacycloalkyl carbonyl cyclic amine compounds | 亚力维克希斯股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | NR1H2 34/4885CHRM2 4331/4885CHRM1 4008/4885 |
| US-20250163041-A1 | AZACYCLOALKYL CARBONYL CYCLIC AMINE COMPOUND | NCF1, ELANE, MPO | NR1H2 411/4885CHRM2 2398/4885CHRM1 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.